Detection of Early Esophageal Cancer by NIR-FME.

Barrett Esophagus Clinical Trial

— ESCEND  

Official title:

A Prospective Follow-up Intervention Study: Detection of Early Esophageal Cancer by Near-infrared Fluoresence Molecular Endoscopy Using Bevacizumab-800CW

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03877601
• Other study ID #: NL68582.042.18
• Status: Recruiting
• Phase: Phase 2
• Start date: July 29, 2019
• Est. completion date: October 1, 2021

Study information

• Verified date: November 2020
• Source: University Medical Center Groningen
• Contact: W.B. Nagengast, MD, PhD, PharmD
• Phone: +31503612620
• Email: w.b.nagengast[@]umcg.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization and the ability for targeted biopsies. Optical molecular imaging of neoplasia associated biomarkers could form a promising technique to accommodate this need. It is known that the biomarker Vascular Endothelial Growth Factor (VEGF) is overexpressed in dysplastic and neoplastic areas in BE segments versus normal tissue and has proven to be a valid target for molecular imaging. The University Medical Center Groningen (UMCG) developed a fluorescent tracer by labeling the VEGF-targeting humanized monoclonal antibody bevacizumab, currently used in anti-cancer therapy, with the fluorescent dye IRDye800CW. The phase I study, named VICE, completed within the UMCG, showed that synchronal use of VEGFA-guided near-infrared fluorescence molecular endoscopy (NIR-FME) and high-definition white light endoscopy (HD-WLE), following topical or systemic tracer administration, could be practiced to recognize dysplastic and early EAC lesions in patients with BE. Furthermore, early lesion detection was improved by ~33% using the topically applied tracer approach compared with HD-WL/NBI endoscopy. With this phase 2 intervention study the investigators aim to statistically confirm previous pilot (Phase I) clinical data showing that the combination of HD-WLE and FME using labelled bevacizumab improves early EC detection over the current clinical standard.

Description:

See brief summary

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: October 1, 2021
• Est. primary completion date: September 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Suspicion or diagnosed LGD, HGD or superficial EAC and planned diagnostic and/or therapeutic endoscopy.

• Age: 18 years or older.

• Written informed consent.

Exclusion Criteria:

• Patients younger than 18 years old

• Submucosal and invasive EAC; EAC with TNM-classification other than T1.

• Radiation therapy for esophageal cancer

• Immunoglobulin allergy

• Chemotherapy, immunotherapy or surgery 28 days before administration of the tracer

• Prior Bevacizumab treatment

• Non-adjustable hypertension

• Medical or psychiatric conditions that compromise the patient's ability to give informed consent.

• Pregnancy or breast feeding.

Related Conditions & MeSH terms

• Barrett Esophagus
• Esophageal Neoplasms

Intervention

Drug:
• Bevacizumab-IRDye800CW
Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.

Diagnostic Test:
• Fluorescence endoscopy
Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen	Groningen

Sponsors (2)

Lead Sponsor	Collaborator
University Medical Center Groningen	Helmholtz Zentrum München

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Nagengast WB, Hartmans E, Garcia-Allende PB, Peters FTM, Linssen MD, Koch M, Koller M, Tjalma JJJ, Karrenbeld A, Jorritsma-Smit A, Kleibeuker JH, van Dam GM, Ntziachristos V. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Gut. 2019 Jan;68(1):7-10. doi: 10.1136/gutjnl-2017-314953. Epub 2017 Dec 15. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fluorescence signal in patients with Barrett's Esophagus	Evaluating the performance of FME with topical administration of Bevacizumab-800CW for detection of neoplasia in BE patients compared to HD-WLE to make an estimation of the diagnostic accuracy in terms of sensitivity and specificity in order to make a power size calculation for the Phase III trial.	During the endoscopic procedure
Secondary	Ex vivo fluorescence singals	Correlate and validate fluorescence signals detected in vivo with ex vivo histopathology grade of dysplasia and VEGF expression	2 years
Secondary	Number of participants with adverse events (AE), serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR).	Data collection as a measure of safety and tolerability regarding administration of Bevacizumab-IRDye800CW	Up to 1 week after administration of tracer
Secondary	Interrogate potential new EC biomarkers	We will perform ex-vivo binding experiments with tracers against GREM1, -SULF1 and -PRKCi on the fresh EMR if available and compare them against the in-vivo WLE/NIR-FME findings. We will analyze the sensitivity and specificity of the novel markers alone or in combination. The targeting moieties will be coupled with different fluorophores allowing for multi-parametric analysis.	2 years